Focus Online CME - Faculty and Disclosures

Principal Faculty and Disclosure of Financial Interests or Other Affiliations With Commercial Organizations

No support from commercial sources was used in the development and production of this CME program.

The American Psychiatric Association requires disclosure by authors, in all CME activities, of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the activity. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content regarding products or services of a commercial interest with which he/she has a financial relationship. The prospective participants must be informed of the author’s affiliation with these commercial entities by an acknowledgement in printed materials [and verbal or visual disclosure to participants at a live session] This policy is intended to openly identify any conflict(s) so that participants in a CME activity are able to form their own judgments about the article. Disclosure for authors is published at the beginning of each CME article. Disclosure of the editors is published below./

Deborah J. Hales M.D.
Coeditor FOCUS, and Director APA Division of Education, Arlington, Virginia.
No financial affiliations with commercial organizations.

Mark H. Rapaport M.D.
Coeditor FOCUS, Chairman, Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, California, Vice Chairman and Professor in Residence Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.
Grant/Research Support: Astra Zeneca*; Pfizer, Inc.; Janssen Pharmaceutica; GlaxoSmithKine; Forest Labs; Lilly; Abbott Laboratories; Corcept Therapeutics; Cyberonics, Inc.; Novartis; Pharmacia Upjohn; Sanofi Synthelabo; Solvay*; Stanley Foundation; Wyeth; UCB Pharma. Inc.; NIMH*; NCCAM* NARSAD, VA Merit Award; Volskwagon Stiefhund. Speaker: Cyberonics, Inc.; Lilly; Forest Labs*; GlaxoSmithKline; Janssen ; Wyeth*; Pharmaceutica; Novartis; Pfizer, Inc. Consultant: Cyberonics, Inc*; Forest Labs; Roche; Pfizer, Inc*; Sanofi Synthelabo; Solvay*; Wyeth*; NIMH*; NIDA; GlaxoSmithKline; NCCR*; Janssen Pharmaceutica*; Neurocrine Biosciences; Lilly; Novartis; Sumitomo; Brain Cells, Inc.* Stockholder: Forest (*Funding in the last 12 months).

Disclosure of Unapproved or Investigational Use of a Product
The APA requires disclosure of discussion or presentation of unapproved uses of a commercial product or investigational use of a product not yet approved for this purpose. Unapproved or investigational uses of products may be discussed in this CME program. "Off-label" use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by the scientific evidence, other scientific literature, and clinical experience.